- Simultaneously detect fatty acid oxidation enzymes, pyruvate dehydrogenase complex components and other biomarkers using Luminex® technology
- Save time, conserve samples, and increase assay specificity
- Accelerate studies of drug-induced mitochondrial toxicity and mitochondrial malfunction linked to a variety of diseases and aging
Billerica, MA—November 17, 2011—EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, today launched three MILLIPLEX® MAP kits for cellular metabolism, the first commercially available multiplexed biomarker assays for this important research area. Compared to traditional biomarker detection techniques such as western blots, the new kits increase assay throughput and specificity.
Based on the Luminex® xMAP® assay technology platform and cellular metabolism antibodies from MitoSciences®, these first three MILLIPLEX® MAP kits enable fast, sensitive, simultaneous quantification of multiple cellular metabolism biomarkers involved in fatty acid oxidation and the pyruvate dehydrogenase complex. Each of the kits provides highly validated and characterized cellular metabolism immunoassay antibodies, all necessary reagents, and optimized protocols.
Studies of cellular metabolic pathways are central to understanding changes in the way that cells and tissues generate energy in response to disease states, drug treatments, dietary changes and genetic mutations. Mitochondrial pathways have been shown to play a role in numerous diseases including cancer, neurodegeneration, cardiovascular disease, and diabetes. The complexity of these pathways, however, makes it difficult to draw conclusions based on the measurement of any individual analyte alone.
“There is a need for assay tools that enable a more holistic measurement of key mitochondrial proteins in disease research and during the drug development process in order to reduce late-stage attrition and safety liability due to toxicity,” notes Linda Meeh, Ph.D., Director of Marketing for Immunoassays and Multiplexing. “These new multiplex kits provide a high-throughput, more specific, more sensitive alternative to traditional methods that measure one analyte at a time.”
“The numerous interactions and complex matrices inherent in multiplex applications highlights the requirement for highly characterized and validated biological affinity reagents, describes James Murray, Ph.D., MitoSciences R&D Manager. MitoSciences’ monoclonal antibodies are thoroughly validated for absolute specificity and optimal sensitivity offering the highest level of fidelity for users of these applications.”
For more information, please visit www.millipore.com/bmia.
About EMD Millipore
EMD Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, EMD Millipore serves as a strategic partner to customers and helps advance the promise of life science.
Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 67 countries and 2010 revenues of $2.2 billion. EMD Millipore is known as Merck Millipore outside of the U.S. and Canada.
Note: Merck KGaA or Merck shall mean Merck KGaA, Darmstadt, Germany
About MitoSciences®
MitoSciences is a leading developer of comprehensive immunoassays and high performance monoclonal antibodies for studying metabolism and apoptosis. An online catalog consists of over 200 products in the areas of metabolism and apoptosis, including antibody cocktails, sandwich ELISA kits, in-cell ELISA, flow cytometry antibodies and enzyme activity assays. MitoSciences have also developed assays on multiplexing platforms, most currently bead-based arrays for benchtop flow cytometers and microplate and slide-based arrays.
MitoSciences , located in Eugene, OR, was acquired by Abcam in May 2011. The product range is available from the MitoSciences and Abcam websites and via authorized distributors. Products are sold under the MitoSciences brand.
Contact:
Leslie Eisenberg (Feinstein Kean Healthcare)
Phone: +1 617 244 3872
Email: [email protected]